| Name | Title | Contact Details |
|---|
Lucidum is the asset discovery company that eliminates blind spots across cloud, security and IT operations. Fortune 500 companies rely on the Lucidum platform and its patent-pending machine learning to discover, triangulate and identify all assets – even previously unknown unknowns – delivering visibility essential to truly secure, manage, and transform your enterprise. Backed by GGV Capital and Silicon Valley CISO Investors (SVCI), Lucidum is based in San Jose, California.
Our intelligent routing software solves complex routing challenges with unrivaled precision to enhance safety, reduce costs and create efficiencies.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Transforming fishers into restorative ocean farmers. Learn more at Greenwave.org
Your Data Creation Partner. Walr delivers digital data solutions, customised to drive your success. Learn more today.